Rice Hall James & Associates LLC Acquires 190,532 Shares of MaxCyte, Inc. (NASDAQ:MXCT)

Rice Hall James & Associates LLC increased its position in MaxCyte, Inc. (NASDAQ:MXCT - Free Report) by 72.2% in the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 454,365 shares of the company's stock after acquiring an additional 190,532 shares during the quarter. Rice Hall James & Associates LLC owned about 0.43% of MaxCyte worth $1,240,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in MXCT. Tower Research Capital LLC TRC increased its holdings in MaxCyte by 123.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 7,564 shares of the company's stock worth $31,000 after acquiring an additional 4,173 shares during the last quarter. Kwmg LLC purchased a new position in MaxCyte during the 1st quarter valued at about $40,000. BNP Paribas Financial Markets purchased a new position in MaxCyte during the 4th quarter valued at about $56,000. New York State Common Retirement Fund grew its holdings in MaxCyte by 131.4% during the 1st quarter. New York State Common Retirement Fund now owns 21,837 shares of the company's stock valued at $60,000 after buying an additional 12,400 shares in the last quarter. Finally, Prudential Financial Inc. purchased a new position in MaxCyte during the 4th quarter valued at about $65,000. Hedge funds and other institutional investors own 68.81% of the company's stock.

Analyst Ratings Changes

Separately, Wall Street Zen raised MaxCyte from a "sell" rating to a "hold" rating in a report on Sunday, June 8th.

MaxCyte Price Performance

MXCT stock traded down $0.11 during mid-day trading on Friday, reaching $2.05. 255,197 shares of the company traded hands, compared to its average volume of 756,175. The company has a market capitalization of $217.63 million, a P/E ratio of -5.11 and a beta of 1.23. MaxCyte, Inc. has a 52-week low of $2.00 and a 52-week high of $5.20. The company has a fifty day moving average price of $2.22 and a 200-day moving average price of $3.10.

MaxCyte (NASDAQ:MXCT - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported ($0.10) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.10). The business had revenue of $10.39 million during the quarter, compared to analyst estimates of $9.05 million. MaxCyte had a negative return on equity of 19.90% and a negative net margin of 110.92%. As a group, analysts forecast that MaxCyte, Inc. will post -0.42 EPS for the current year.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.